Sort publications on year

  • Pharmaco-Economics

    Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims.

    DETOURNAY B, DEBOUVERIE M, PEREIRA O, SEYER D, SOUDAN M, COUROUVE L, JHOMA K, EPSTEIN J, GUILLEMIN F.

    Mult Scler Relat Disord ; 2019;36

  • Pharmaco-Economics

    Le coût de l’obésité en France

    DETOURNAY B.

    Med Mal Metab ; 2021(Online)

  • Pharmaco-Economics

    Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France.

    POLACK B, TROSSAËRT M, COUSIN M, BAFFERT S, PRUVOT A, GODARD C.

    Haemophilia ; 2020;27(1)e1-e11

  • Pharmaco-Economics

    Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study

    HEQUET D, HUCHON C, SOILLY AL, ASSELAIN B, BERSENEFF H, TRICHOT C, COMBES A, ALVES K, NGUYEN T, ROUZIER R, BAFFERT S.

    PLoS One ; 2019;14(7)

  • Pharmaco-Economics

    Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.

    HOOGENDOORN M, CORRO RAMOS I, BALDWIN M, LUCIANI L, FABRON C, DETOURNAY B, PMH RUTTEN-VAN MÖLKEN M.

    Int J Chron Obstruct Pulmon Dis ; 2019;14:447-456

  • Pharmaco-Economics

    Cost-effectiveness of web-based patient-reported outcome surveillance in lung cancer patients.

    LIZÉE T, BASCH E, TRÉMOLIÈRES P, VOOG E, DOMONT J, PEYRAGA G, URBAN T, BENNOUNA J, SEPTANS A-L, BALAVOINE M, DETOURNAY B, DENIS F.

    J Thorac Oncol ; 2019;14(6):1012-1020

  • Pharmaco-Economics

    [Standard or specific unit costs: Which criteria for choosing an economic evaluation of health strategies in multicentric studies?]

    MARGIER J, BAFFERT S, LE CORROLLER-SORIANO AG, French Costing Group.

    Rev Epidemiol Sante Publique ; 2018;66(S2):S93-S99

  • Pharmaco-Economics

    Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study

    ARFI A, BAFFERT S, SOILLY AL, HUCHON C, REYAL F, ASSELAIN B, NEFFATI S, ROUZIER R, HÉQUET D.

    BMJ Open ; 2018;8(5):e020276

  • Pharmaco-Economics

    Multiple Source of Information to Characterize the Clinical, Therapeutic Management and Economic Burden of Patients with Multiple Sclerosis in France.

    EPSTEIN J, DETOURNAY B , GUILLEMIN F, DEBOUVERIE M, COUSIN M, TEHARD B, GAROT T, BITOUN L, SOUDANT M , DEPOORTERE PH, PAU D

    Value in Health ; 2017;20(9):a719

  • Pharmaco-Economics

    Le coût des hospitalisations pour hypoglycémie en France chez les patients diabétiques de type 2

    DETOURNAY B, HALIMI S, LEVY P, BEC M, TORRETON E, DEJAGER S.

    Revue d'Épidémiologie et de Santé Publique ; 2017;65(S3):S137-S138

  • Pharmaco-Economics

    Effect of Multiple Sclerosis on Work Productivity

    DETOURNAY B, COUSIN M, GOURMELEN J, PAU D, PINGUET JM, TEHARD B, COZZONE D

    Value in Health ; 2017;20(9):a725

  • Pharmaco-Economics

    The Direct Cost of Patients With Multiple Sclerosis In France

    DETOURNAY B, COUSIN M, GOURMELEN J, L. BITOUN L, PAU D, COZZONE D, B. TEHARD B

    Value in Health ; 2017;20(9):a721

  • Pharmaco-Economics

    What is the budget impact of a new treatment or new health technology arriving on the market?

    DERVAUX B, LE FUR C, DUBOIS S, JOSSERAN A, DETOURNAY B; participants of round table No. 3 of Giens XXXIII

    Therapie ; 2017;72(1):93-103

  • Pharmaco-Economics

    Quel impact budgétaire pour l’arrivée d’un nouveau traitement ou d’une nouvelle technologie de santé ?

    DERVAUX B, LE FUR C, DUBOIS S, JOSSERAN A, DETOURNAY B; les participants à la table ronde n(o) 3 de Giens XXXIII.

    Therapie ; 2017;72(1):81-91

  • Pharmaco-Economics

    Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France

    FERNANDEZ H, JOURDAIN O, VILLEFRANQUE V, LEHMANN M, LAFUMA A, TRANCART M.

    BMJ Open ; 2017;7(9):e015571